ELI LILLY (LLY)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for LLY
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LLY | 59 | ["Nobel Laureate", "expert in chemical biology", "decades of groundbreaking research experience", "founding and advising various biotechnology companies", "commercialization experience in life sciences"] | ["Ethics and Compliance", "Science and Technology"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALNY | Independent Director | 58 | ["Anne T. and Robert M. Bass Professor of Chemistry at Stanford University since 2015","Baker Family Director of Stanford’s Sarafan ChEM-H Institute since 2021","Investigator at the Howard Hughes Medical Institute since 2000","Former professor of Chemistry and Molecular and Cell Biology at the University of California, Berkeley","Jointly awarded the 2022 Nobel Prize in Chemistry","Member of the National Academy of Sciences, the National Academy of Medicine, and National Academy of Inventors","Served as a director of OmniAb, Inc. and Eli Lilly and Company"] | ["Nominating and Corporate Governance Committee","Science and Technology Committee"] | 2025 |
| OABI | Anne T. and Robert M. Bass Professor of Chemistry, a professor of Chemical and Systems Biology and Radiology and the Baker Family Co-Director of Stanford ChEM-H. | 56 | [] | ["NCG Committee","Science & Technology Committee Chair"] | 2023 |
Biography sourced from the proxy statement filing.
Dr. Bertozzi is a world-renowned Nobel Laureate, scientist, academician, and pioneer in chemical biology who provides valuable leadership to the board's oversight of Lilly's discovery and development programs. Dr. Bertozzi has decades of groundbreaking research experience, offering a valuable perspective and resource to the board and management in pharmaceutical research and discovery across multiple therapeutic areas. Through her work founding and advising various biotechnology companies, Dr. Bertozzi has a deep understanding of the challenges, perspectives, and opportunities for translating basic scientific research into therapeutic application. Dr. Bertozzi also brings commercialization experience to the board through her work founding biotechnology companies and leadership roles in more than a dozen academic and scientific advisory boards and life sciences companies, bridging academic discovery and pharmaceutical innovation. Age: 59 Director Since: 2025 Board Committees: Ethics and Compliance Science and Technology Other Public Boards: OmniAb, Inc. Recent Prior Public Boards: Alnylam Pharmaceuticals, Inc. Key Skills: CAREER HIGHLIGHTS Stanford University Anne T. and Robert M. Bass Professor of Chemistry, Professor of Chemical and Systems Biology and Radiology by courtesy (2015 - present) Baker Family Director of Sarafan ChEM-H (2017 - present) Howard Hughes Medical Institute Investigator (2000 - present) OTHER HIGHLIGHTS Recipient of numerous prizes and honors, including: Nobel Prize in Chemistry Lemelson-MIT award for inventors Whistler Award Ernst Schering Prize MacArthur Foundation Fellowship Member, National Academy of Medicine; National Academy of Sciences; American Academy of Arts and Sciences; and German Academy of Sciences Leopoldina